Shamasunder Acharya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shamasunder Acharya has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Coda
Podiatry, School of Health Sciences, College of Health, Medicine and Wellbeing - The University of Newcastle, Newcastle, Australia; 'Equity in Health and Wellbeing Research Program', Hunter Medical Research Institute (HMRI), New South Wales, Australia
4 shared publications - Antoni Fellas
School of Health Sciences, College of Health, Medicine and Wellbeing, the University of Newcastle Callaghan New South Wales Australia
4 shared publications - Dean Sculley
School of Bioscience and Pharmacy, University of Newcastle, Ourimbah, NSW 2258, Australia
4 shared publications - Derek Santos
Queen Margaret University
4 shared publications - Katie Wynne
Equity in Health and Wellbeing Program, Hunter Medical Research Institute (HMRI), New Lambton Heights, NSW, Australia
4 shared publications - Pooshan Navathe
Central Queensland Health, Rockhampton, Australia
4 shared publications
Latest Publications
- Open Access
Does the Diabetes Alliance Program Plus Reduce Hospitalisations in Patients with Type 2 Diabetes Attending Primary Care Practices? A Target Trial Protocol for Emulating a Cluster Trial Using Linked General Practice and Tertiary Health Data
Background Effective management of type 2 diabetes remain a challenge for health services in Australia. Rural and remote communities in particular are at a higher risk of diabetes-related complications due to reduced access to specialist services, making the role of general practices all the more important in the provision of diabetes care. Integrated care targeted around increasing capacity to rural general practices in the treatment of type 2 diabetes may reduce the disparity in health outcomes among rural and remote patients suffering from type-2 diabetes. This protocol aims to describe a causal approach for the evaluation of a specialist-led integrated model of care delivered to general practices using large administrative health data. Methods and analysis This will be an observational cohort study using linked general practice and hospital data from the Lumos program. This protocol adopts the target trial framework approach described by Hernan et al and the estimands framework proposed by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). We describe the data structure and statistical analysis plan that would be required for causal inferences. The target causal estimand is the effect of the Diabetes Alliance Program Plus integrated care intervention, among general practice active-attending adult patients with current and new diagnoses of type 2 diabetes, on three-year hospitalisation rates wherein type 2 diabetes is the principal diagnosis. Causal effect estimates and the precision in these estimates will be quantified. Ethics and dissemination The Diabetes Alliance Program Plus has ethics approval from the Hunter New England Human Research Ethics Committee (2024/ETH01649), with approval registered with the University of Newcastle (R-2024-0073). The Lumos data asset is also ethically approved by the Population Health Services Research Ethics Committee (PHSREC; 2019/ETH00660), and DAP+ has received approval by their Governance Committee for the evaluation in this protocol. The analysis and interpretation of the results will be contingent of the quality of the observational data. Findings will be disseminated to local stake holders and submitted to scientific peer-reviewed journals. Data statement The data will not be made publicly available due to privacy, ethical, and data governance restrictions. Strengths and limitations of this study This protocol incorporates design principles from randomised trials to the analysis plan of a large health-service data asset, which allowed us to construct a clear target causal estimand. This approach describes a novel two-step propensity matching approach to account for cluster-level confounding in observational analyses in order to create a statistical analogue of cluster randomisation. The statistical methods described in this protocol describes an appropriate method comparing individual-level effects across clusters, in cases where an intervention results in clusters of all-treated and all-not-treated individuals. The implementation of this protocol will be limited by the availability and quality of data collection in the proposed data asset.
Open AccessDoes the Diabetes Alliance Program Plus Reduce Hospitalisations in Patients with Type 2 Diabetes Attending Primary Care Practices? A Target Trial Protocol for Emulating a Cluster Trial Using Linked General Practice and Tertiary Health Data
Background Effective management of type 2 diabetes remain a challenge for health services in Australia. Rural and remote communities in particular are at a higher risk of diabetes-related complications due to reduced access to specialist services, making the role of general practices all the more important in the provision of diabetes care. Integrated care targeted around increasing capacity to rural general practices in the treatment of type 2 diabetes may reduce the disparity in health outcomes among rural and remote patients suffering from type-2 diabetes. This protocol aims to describe a causal approach for the evaluation of a specialist-led integrated model of care delivered to general practices using large administrative health data. Methods and analysis This will be an observational cohort study using linked general practice and hospital data from the Lumos program. This protocol adopts the target trial framework approach described by Hernan et al and the estimands framework proposed by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). We describe the data structure and statistical analysis plan that would be required for causal inferences. The target causal estimand is the effect of the Diabetes Alliance Program Plus integrated care intervention, among general practice active-attending adult patients with current and new diagnoses of type 2 diabetes, on three-year hospitalisation rates wherein type 2 diabetes is the principal diagnosis. Causal effect estimates and the precision in these estimates will be quantified. Ethics and dissemination The Diabetes Alliance Program Plus has ethics approval from the Hunter New England Human Research Ethics Committee (2024/ETH01649), with approval registered with the University of Newcastle (R-2024-0073). The Lumos data asset is also ethically approved by the Population Health Services Research Ethics Committee (PHSREC; 2019/ETH00660), and DAP+ has received approval by their Governance Committee for the evaluation in this protocol. The analysis and interpretation of the results will be contingent of the quality of the observational data. Findings will be disseminated to local stake holders and submitted to scientific peer-reviewed journals. Data statement The data will not be made publicly available due to privacy, ethical, and data governance restrictions. Strengths and limitations of this study This protocol incorporates design principles from randomised trials to the analysis plan of a large health-service data asset, which allowed us to construct a clear target causal estimand. This approach describes a novel two-step propensity matching approach to account for cluster-level confounding in observational analyses in order to create a statistical analogue of cluster randomisation. The statistical methods described in this protocol describes an appropriate method comparing individual-level effects across clusters, in cases where an intervention results in clusters of all-treated and all-not-treated individuals. The implementation of this protocol will be limited by the availability and quality of data collection in the proposed data asset.
- Open Access
- 12 April 2025
- Published by Oxford University Press (OUP) in Family Practice
- Vol. 42  (3)
Australian practice nurses’ perspectives on integrating specialist diabetes care with primary care: a qualitative study
Background: In 2015, the Australian Diabetes Alliance Program (DAP) was implemented in the Hunter New England Local Health District, New South Wales as a collaboration with the Hunter Medicare Local. DAP integrates specialist teams within primary care practices, delivering case conferencing, practice performance reviews, and education sessions. Objective: To report on practice nurses (PNs) perspectives on the impact of the DAP on their skills, knowledge, and approach in delivering care for adults with type 2 diabetes. Methods: Three primary care practices with high rates of monitoring haemoglobin A1c (HbA1c) levels (> 90% of patients annually) and three practices with lower rates of monitoring HbA1c levels (< 80% of patients annually) from DAP provided the sampling frame. Interviews were conducted with six PNs, which were transcribed and analysed using codebook thematic analysis. Results: Overall, DAP was viewed favourably by PNs. Significant improvements in knowledge and skills were reported relating to administering antihyperglycemic agents, insulin, and other injectable therapy, as well as dietary modifications for diabetes management. PNs transferred this knowledge and skills to other patients not participating in DAP. An improvement in the delivery of diabetes care, rather than a change in approach, was also reported by PNs. However, the amount of preparation required for case conferencing in the program was identified as a burden to PNs. Conclusions: PNs were supportive of DAP and identified knowledge gains that were transferable to other patients. The administrative burdens on PNs need to be considered for scalability of the program.
- 12 April 2025
- Published by Oxford University Press (OUP) in Family Practice
- Vol. 42  (3)
Open AccessAustralian practice nurses’ perspectives on integrating specialist diabetes care with primary care: a qualitative study
Background: In 2015, the Australian Diabetes Alliance Program (DAP) was implemented in the Hunter New England Local Health District, New South Wales as a collaboration with the Hunter Medicare Local. DAP integrates specialist teams within primary care practices, delivering case conferencing, practice performance reviews, and education sessions. Objective: To report on practice nurses (PNs) perspectives on the impact of the DAP on their skills, knowledge, and approach in delivering care for adults with type 2 diabetes. Methods: Three primary care practices with high rates of monitoring haemoglobin A1c (HbA1c) levels (> 90% of patients annually) and three practices with lower rates of monitoring HbA1c levels (< 80% of patients annually) from DAP provided the sampling frame. Interviews were conducted with six PNs, which were transcribed and analysed using codebook thematic analysis. Results: Overall, DAP was viewed favourably by PNs. Significant improvements in knowledge and skills were reported relating to administering antihyperglycemic agents, insulin, and other injectable therapy, as well as dietary modifications for diabetes management. PNs transferred this knowledge and skills to other patients not participating in DAP. An improvement in the delivery of diabetes care, rather than a change in approach, was also reported by PNs. However, the amount of preparation required for case conferencing in the program was identified as a burden to PNs. Conclusions: PNs were supportive of DAP and identified knowledge gains that were transferable to other patients. The administrative burdens on PNs need to be considered for scalability of the program.
- Open Access
- 3 December 2024
- Published by JMIR Publications Inc. in JMIR mHealth and uHealth
- Vol. 12  (1) , e54826
The Role of Smartwatch Technology in the Provision of Care for Type 1 or 2 Diabetes Mellitus or Gestational Diabetes: Systematic Review
Background: The use of smart technology in the management of all forms of diabetes mellitus has grown significantly in the past 10 years. Technologies such as the smartwatch have been proposed as a method of assisting in the monitoring of blood glucose levels as well as other alert prompts such as medication adherence and daily physical activity targets. These important outcomes reach across all forms of diabetes and have the potential to increase compliance of self-monitoring with the aim of improving long-term outcomes such as hemoglobin A 1c (HbA 1c ). Objective: This systematic review aims to explore the literature for evidence of smartwatch technology in type 1, 2, and gestational diabetes. Methods: A systematic review was undertaken by searching Ovid MEDLINE and CINAHL databases. A second search using all identified keywords and index terms was performed on Ovid MEDLINE (January 1966 to August 2023), Embase (January 1980 to August 2023), Cochrane Central Register of Controlled Trials (CENTRAL, the Cochrane Library, latest issue), CINAHL (from 1982), IEEE Xplore, ACM Digital Libraries, and Web of Science databases. Type 1, type 2, and gestational diabetes were eligible for inclusion. Quantitative studies such as prospective cohort or randomized clinical trials that explored the feasibility, usability, or effect of smartwatch technology in people with diabetes were eligible. Outcomes of interest were changes in blood glucose or HbA 1c , physical activity levels, medication adherence, and feasibility or usability scores. Results: Of the 8558 titles and abstracts screened, 5 studies were included for qualitative synthesis in this review. A total of 322 participants with either type 1 or type 2 diabetes mellitus were included in the review. A total of 4 studies focused on the feasibility and usability of smartwatch technology in diabetes management. One study conducted a proof-of-concept randomized clinical trial including smartwatch technology for exercise time prescriptions for participants with type 2 diabetes mellitus. Adherence of participants to smartwatch technology varied between included studies, with one reporting input submissions of 58% and another reporting that participants logged 50% more entries than they were required to. One study reported significantly improved glycemic control with integrated smartwatch technology, with increased exercise prescriptions; however, this study was not powered and required a longer observational period. Conclusions: This systematic review has highlighted the lack of robust randomized clinical trials that explore the efficacy of smartwatch technology in the management of patients with type 1, type 2, and gestational diabetes. Further research is required to establish the role of integrated smartwatch technology in important outcomes such as glycemic control, exercise participation, drug adherence, and diet monitoring in people with all forms of diabetes mellitus.
- 3 December 2024
- Published by JMIR Publications Inc. in JMIR mHealth and uHealth
- Vol. 12  (1) , e54826
Open AccessThe Role of Smartwatch Technology in the Provision of Care for Type 1 or 2 Diabetes Mellitus or Gestational Diabetes: Systematic Review
Background: The use of smart technology in the management of all forms of diabetes mellitus has grown significantly in the past 10 years. Technologies such as the smartwatch have been proposed as a method of assisting in the monitoring of blood glucose levels as well as other alert prompts such as medication adherence and daily physical activity targets. These important outcomes reach across all forms of diabetes and have the potential to increase compliance of self-monitoring with the aim of improving long-term outcomes such as hemoglobin A 1c (HbA 1c ). Objective: This systematic review aims to explore the literature for evidence of smartwatch technology in type 1, 2, and gestational diabetes. Methods: A systematic review was undertaken by searching Ovid MEDLINE and CINAHL databases. A second search using all identified keywords and index terms was performed on Ovid MEDLINE (January 1966 to August 2023), Embase (January 1980 to August 2023), Cochrane Central Register of Controlled Trials (CENTRAL, the Cochrane Library, latest issue), CINAHL (from 1982), IEEE Xplore, ACM Digital Libraries, and Web of Science databases. Type 1, type 2, and gestational diabetes were eligible for inclusion. Quantitative studies such as prospective cohort or randomized clinical trials that explored the feasibility, usability, or effect of smartwatch technology in people with diabetes were eligible. Outcomes of interest were changes in blood glucose or HbA 1c , physical activity levels, medication adherence, and feasibility or usability scores. Results: Of the 8558 titles and abstracts screened, 5 studies were included for qualitative synthesis in this review. A total of 322 participants with either type 1 or type 2 diabetes mellitus were included in the review. A total of 4 studies focused on the feasibility and usability of smartwatch technology in diabetes management. One study conducted a proof-of-concept randomized clinical trial including smartwatch technology for exercise time prescriptions for participants with type 2 diabetes mellitus. Adherence of participants to smartwatch technology varied between included studies, with one reporting input submissions of 58% and another reporting that participants logged 50% more entries than they were required to. One study reported significantly improved glycemic control with integrated smartwatch technology, with increased exercise prescriptions; however, this study was not powered and required a longer observational period. Conclusions: This systematic review has highlighted the lack of robust randomized clinical trials that explore the efficacy of smartwatch technology in the management of patients with type 1, type 2, and gestational diabetes. Further research is required to establish the role of integrated smartwatch technology in important outcomes such as glycemic control, exercise participation, drug adherence, and diet monitoring in people with all forms of diabetes mellitus.
- Open Access
- 10 September 2024
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 24  (1) , 1-9
Spillover effects from a type 2 diabetes integrated model of care in 22,706 Australians: an open cohort stepped wedge trial
Background: Many Australian adults are not receiving timely or effective diabetes management to prevent or delay the onset of diabetes related complications. Integrated care, a worldwide trend in healthcare reform, aims to reduce the fragmented delivery of health services and improve outcomes. This study aimed to test whether a specialist-led integrated model of care provided to a small subset of patients in general practices leads to spillover clinical improvements in all patients of the practice with type 2 diabetes. Methods: Seventy-two general practice sites (clusters) in New South Wales, Australia received the Diabetes Alliance intervention, creating a non-randomised open cohort stepped wedge trial. The intervention comprised of case conferencing, delivered directly to a small proportion of adults with type 2 diabetes (n = 1,072) of the general practice sites; as well as practice feedback, education and training. Spillover clinical improvements were assessed on all adults with type 2 diabetes within the general practice sites (n = 22,706), using practice level data recorded in the MedicineInsight electronic database, compared before and after the intervention. Outcome measures included frequency of diabetes screening tests in line with the Annual Cycle of Care, and clinical results for weight, blood pressure, HbA1c, lipids, and kidney function. Results: Compared to before Diabetes Alliance, the odds of all practice patients receiving screening tests at or above the recommended intervals were significantly higher for all recommended tests after Diabetes Alliance (odds ratio range 1.41–4.45, p < 0.0001). Significant improvements in clinical outcomes were observed for weight (absolute mean difference: -1.38 kg), blood pressure (systolic − 1.12 mmHg, diastolic − 1.18 mmHg), HbA1c (-0.03% at the mean), total cholesterol (-0.11 mmol/L), and triglycerides (-0.02 mmol/L) (p < 0.05). There were small but significant declines in kidney function. Conclusions: Integrated care delivered to a small subset of patients with type 2 diabetes across a large geographic region has spillover benefits that improve the process measures and clinical outcomes for all practice patients with type 2 diabetes. Trial registration: ACTRN12622001438741; 10th November 2022, retrospectively registered: https://www.anzctr.org.au/ACTRN12622001438741.aspx.
- 10 September 2024
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 24  (1) , 1-9
Open AccessSpillover effects from a type 2 diabetes integrated model of care in 22,706 Australians: an open cohort stepped wedge trial
Background: Many Australian adults are not receiving timely or effective diabetes management to prevent or delay the onset of diabetes related complications. Integrated care, a worldwide trend in healthcare reform, aims to reduce the fragmented delivery of health services and improve outcomes. This study aimed to test whether a specialist-led integrated model of care provided to a small subset of patients in general practices leads to spillover clinical improvements in all patients of the practice with type 2 diabetes. Methods: Seventy-two general practice sites (clusters) in New South Wales, Australia received the Diabetes Alliance intervention, creating a non-randomised open cohort stepped wedge trial. The intervention comprised of case conferencing, delivered directly to a small proportion of adults with type 2 diabetes (n = 1,072) of the general practice sites; as well as practice feedback, education and training. Spillover clinical improvements were assessed on all adults with type 2 diabetes within the general practice sites (n = 22,706), using practice level data recorded in the MedicineInsight electronic database, compared before and after the intervention. Outcome measures included frequency of diabetes screening tests in line with the Annual Cycle of Care, and clinical results for weight, blood pressure, HbA1c, lipids, and kidney function. Results: Compared to before Diabetes Alliance, the odds of all practice patients receiving screening tests at or above the recommended intervals were significantly higher for all recommended tests after Diabetes Alliance (odds ratio range 1.41–4.45, p < 0.0001). Significant improvements in clinical outcomes were observed for weight (absolute mean difference: -1.38 kg), blood pressure (systolic − 1.12 mmHg, diastolic − 1.18 mmHg), HbA1c (-0.03% at the mean), total cholesterol (-0.11 mmol/L), and triglycerides (-0.02 mmol/L) (p < 0.05). There were small but significant declines in kidney function. Conclusions: Integrated care delivered to a small subset of patients with type 2 diabetes across a large geographic region has spillover benefits that improve the process measures and clinical outcomes for all practice patients with type 2 diabetes. Trial registration: ACTRN12622001438741; 10th November 2022, retrospectively registered: https://www.anzctr.org.au/ACTRN12622001438741.aspx.
- Open Access
- 23 November 2023
- Published by JMIR Publications Inc. in JMIR Preprints
The role of SmartWatch Technology in the provision of care for type 1 or type 2 Diabetes Mellitus or Gestational Diabetes: a systematic review. (Preprint)
BACKGROUND The use of Smart technology in the management of all forms of diabetes mellitus has grown significantly in the past ten years. Technologies such as the SmartWatch have been proposed as a method of assisting in the monitoring of blood glucose levels as well as other alert prompts such as medication adherence and daily physical activity targets. These important outcomes reach across all forms of diabetes and have the potential to increase compliance of self-monitoring with the aim of improving long term outcomes such as HbA1c. OBJECTIVE This systematic review aims to explore the literature for evidence of SmartWatch technology in type 1,2 and gestational diabetes. METHODS A systematic review was undertaken by searching Ovid MEDLINE and CINAHL databases. A second search using all identified keywords and index terms was performed on Ovid MEDLINE (January 1966 to August 2023), EMBASE (January 1980 to August 2023), Cochrane Central Register of Controlled Trials (CENTRAL) (the Cochrane Library, latest issue), CINAHL (from 1982), IEEE Xplore, and ACM Digital Libraries, and Web of Science databases. RESULTS Five studies were included for qualitative synthesis in this review, however, none of these studies were randomised clinical trials and published research is currently focusing on usability and feasibility. CONCLUSIONS This systematic review has highlighted the lack of robust randomised clinical trials that explore the efficacy of SmartWatch technology in the management of patients with type 1, 2 and gestational diabetes.
- 23 November 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessThe role of SmartWatch Technology in the provision of care for type 1 or type 2 Diabetes Mellitus or Gestational Diabetes: a systematic review. (Preprint)
BACKGROUND The use of Smart technology in the management of all forms of diabetes mellitus has grown significantly in the past ten years. Technologies such as the SmartWatch have been proposed as a method of assisting in the monitoring of blood glucose levels as well as other alert prompts such as medication adherence and daily physical activity targets. These important outcomes reach across all forms of diabetes and have the potential to increase compliance of self-monitoring with the aim of improving long term outcomes such as HbA1c. OBJECTIVE This systematic review aims to explore the literature for evidence of SmartWatch technology in type 1,2 and gestational diabetes. METHODS A systematic review was undertaken by searching Ovid MEDLINE and CINAHL databases. A second search using all identified keywords and index terms was performed on Ovid MEDLINE (January 1966 to August 2023), EMBASE (January 1980 to August 2023), Cochrane Central Register of Controlled Trials (CENTRAL) (the Cochrane Library, latest issue), CINAHL (from 1982), IEEE Xplore, and ACM Digital Libraries, and Web of Science databases. RESULTS Five studies were included for qualitative synthesis in this review, however, none of these studies were randomised clinical trials and published research is currently focusing on usability and feasibility. CONCLUSIONS This systematic review has highlighted the lack of robust randomised clinical trials that explore the efficacy of SmartWatch technology in the management of patients with type 1, 2 and gestational diabetes.
- Open Access
- 15 March 2023
- Published by JMIR Publications Inc. in JMIR Diabetes
- Vol. 8  (1) , e42389
The Clinical Impact of Flash Glucose Monitoring—a Digital Health App and Smartwatch Technology in Patients With Type 2 Diabetes: Scoping Review
Background: Type 2 diabetes has a growing prevalence and confers significant cost burden to the health care system, raising the urgent need for cost-effective and easily accessible solutions. The management of type 2 diabetes requires significant commitment from the patient, caregivers, and the treating team to optimize clinical outcomes and prevent complications. Technology and its implications for the management of type 2 diabetes is a nascent area of research. The impact of some of the more recent technological innovations in this space, such as continuous glucose monitoring, flash glucose monitoring, web-based applications, as well as smartphone- and smart watch–based interactive apps has received limited attention in the research literature. Objective: This scoping review aims to explore the literature available on type 2 diabetes, flash glucose monitoring, and digital health technology to improve diabetic clinical outcomes and inform future research in this area. Methods: A scoping review was undertaken by searching Ovid MEDLINE and CINAHL databases. A second search using all identified keywords and index terms was performed on Ovid MEDLINE (January 1966 to July 2021), EMBASE (January 1980 to July 2021), Cochrane Central Register of Controlled Trials (CENTRAL; the Cochrane Library, latest issue), CINAHL (from 1982), IEEE Xplore, ACM Digital Libraries, and Web of Science databases. Results: There were very few studies that have explored the use of mobile health and flash glucose monitoring in type 2 diabetes. These studies have explored somewhat disparate and limited areas of research, and there is a distinct lack of methodological rigor in this area of research. The 3 studies that met the inclusion criteria have addressed aspects of the proposed research question. Conclusions: This scoping review has highlighted the lack of research in this area, raising the opportunity for further research in this area, focusing on the clinical impact and feasibility of the use of multiple technologies, including flash glucose monitoring in the management of patients with type 2 diabetes.
- 15 March 2023
- Published by JMIR Publications Inc. in JMIR Diabetes
- Vol. 8  (1) , e42389
Open AccessThe Clinical Impact of Flash Glucose Monitoring—a Digital Health App and Smartwatch Technology in Patients With Type 2 Diabetes: Scoping Review
Background: Type 2 diabetes has a growing prevalence and confers significant cost burden to the health care system, raising the urgent need for cost-effective and easily accessible solutions. The management of type 2 diabetes requires significant commitment from the patient, caregivers, and the treating team to optimize clinical outcomes and prevent complications. Technology and its implications for the management of type 2 diabetes is a nascent area of research. The impact of some of the more recent technological innovations in this space, such as continuous glucose monitoring, flash glucose monitoring, web-based applications, as well as smartphone- and smart watch–based interactive apps has received limited attention in the research literature. Objective: This scoping review aims to explore the literature available on type 2 diabetes, flash glucose monitoring, and digital health technology to improve diabetic clinical outcomes and inform future research in this area. Methods: A scoping review was undertaken by searching Ovid MEDLINE and CINAHL databases. A second search using all identified keywords and index terms was performed on Ovid MEDLINE (January 1966 to July 2021), EMBASE (January 1980 to July 2021), Cochrane Central Register of Controlled Trials (CENTRAL; the Cochrane Library, latest issue), CINAHL (from 1982), IEEE Xplore, ACM Digital Libraries, and Web of Science databases. Results: There were very few studies that have explored the use of mobile health and flash glucose monitoring in type 2 diabetes. These studies have explored somewhat disparate and limited areas of research, and there is a distinct lack of methodological rigor in this area of research. The 3 studies that met the inclusion criteria have addressed aspects of the proposed research question. Conclusions: This scoping review has highlighted the lack of research in this area, raising the opportunity for further research in this area, focusing on the clinical impact and feasibility of the use of multiple technologies, including flash glucose monitoring in the management of patients with type 2 diabetes.
- Open Access
- 1 September 2022
- Published by JMIR Publications Inc. in JMIR Preprints
The Clinical Impact of Flash Glucose Monitoring—a Digital Health App and Smartwatch Technology in Patients With Type 2 Diabetes: Scoping Review (Preprint)
BACKGROUND Type 2 diabetes has a growing prevalence and confers significant cost burden to the health care system, raising the urgent need for cost-effective and easily accessible solutions. The management of type 2 diabetes requires significant commitment from the patient, caregivers, and the treating team to optimize clinical outcomes and prevent complications. Technology and its implications for the management of type 2 diabetes is a nascent area of research. The impact of some of the more recent technological innovations in this space, such as continuous glucose monitoring, flash glucose monitoring, web-based applications, as well as smartphone- and smart watch–based interactive apps has received limited attention in the research literature. OBJECTIVE This scoping review aims to explore the literature available on type 2 diabetes, flash glucose monitoring, and digital health technology to improve diabetic clinical outcomes and inform future research in this area. METHODS A scoping review was undertaken by searching Ovid MEDLINE and CINAHL databases. A second search using all identified keywords and index terms was performed on Ovid MEDLINE (January 1966 to July 2021), EMBASE (January 1980 to July 2021), Cochrane Central Register of Controlled Trials (CENTRAL; the Cochrane Library, latest issue), CINAHL (from 1982), IEEE Xplore, ACM Digital Libraries, and Web of Science databases. RESULTS There were very few studies that have explored the use of mobile health and flash glucose monitoring in type 2 diabetes. These studies have explored somewhat disparate and limited areas of research, and there is a distinct lack of methodological rigor in this area of research. The 3 studies that met the inclusion criteria have addressed aspects of the proposed research question. CONCLUSIONS This scoping review has highlighted the lack of research in this area, raising the opportunity for further research in this area, focusing on the clinical impact and feasibility of the use of multiple technologies, including flash glucose monitoring in the management of patients with type 2 diabetes.
- 1 September 2022
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessThe Clinical Impact of Flash Glucose Monitoring—a Digital Health App and Smartwatch Technology in Patients With Type 2 Diabetes: Scoping Review (Preprint)
BACKGROUND Type 2 diabetes has a growing prevalence and confers significant cost burden to the health care system, raising the urgent need for cost-effective and easily accessible solutions. The management of type 2 diabetes requires significant commitment from the patient, caregivers, and the treating team to optimize clinical outcomes and prevent complications. Technology and its implications for the management of type 2 diabetes is a nascent area of research. The impact of some of the more recent technological innovations in this space, such as continuous glucose monitoring, flash glucose monitoring, web-based applications, as well as smartphone- and smart watch–based interactive apps has received limited attention in the research literature. OBJECTIVE This scoping review aims to explore the literature available on type 2 diabetes, flash glucose monitoring, and digital health technology to improve diabetic clinical outcomes and inform future research in this area. METHODS A scoping review was undertaken by searching Ovid MEDLINE and CINAHL databases. A second search using all identified keywords and index terms was performed on Ovid MEDLINE (January 1966 to July 2021), EMBASE (January 1980 to July 2021), Cochrane Central Register of Controlled Trials (CENTRAL; the Cochrane Library, latest issue), CINAHL (from 1982), IEEE Xplore, ACM Digital Libraries, and Web of Science databases. RESULTS There were very few studies that have explored the use of mobile health and flash glucose monitoring in type 2 diabetes. These studies have explored somewhat disparate and limited areas of research, and there is a distinct lack of methodological rigor in this area of research. The 3 studies that met the inclusion criteria have addressed aspects of the proposed research question. CONCLUSIONS This scoping review has highlighted the lack of research in this area, raising the opportunity for further research in this area, focusing on the clinical impact and feasibility of the use of multiple technologies, including flash glucose monitoring in the management of patients with type 2 diabetes.
- Open Access
- 22 April 2022
- Published by Springer Nature in Acta Diabetologica
- Vol. 59  (7) , 965-975
The effect of zinc supplementation on glucose homeostasis: a randomised double-blind placebo-controlled trial
Aims: The burden and health costs of Type 2 Diabetes Mellitus continue to increase globally and prevention strategies in at-risk people need to be explored. Previous work, in both animal models and humans, supports the role of zinc in improving glucose homeostasis. We, therefore, aimed to test the effectiveness of zinc supplementation on glycaemic control in pre-diabetic adults. Methods: We conducted a randomized, double-blind, placebo-controlled trial across 10 General Practitioner (GP) practices in NSW, Australia. The trial is known as Zinc in Preventing the Progression of pre-Diabetes (ZIPPeD)Study. Pre-diabetic (haemoglobin A1c [HbA1c] 5.7–6.4%, 39–46 mmol/mol) men and women (N = 98) were all assigned to a free state government telephone health coaching service (New South Wales Get Healthy Information and Coaching Service) and then randomised to either daily 30 mg zinc gluconate or placebo. Blood tests were collected at baseline, 1, 6 and 12 months for the primary outcomes (HbA1c, fasting blood glucose (FBG)); secondary outcomes included Homeostasis Model Assessment 2 (HOMA 2) parameters, lipids, body weight, height, waist circumference, blood pressure and pulse. Results: The baseline-adjusted mean group difference at 6 months, expressed as treatment–placebo, (95% CI) was −0.02 (−0.14, 0.11, p = 0.78) for HbA1c and 0.17 (−0.07, 0.42; p = 0.17) for FBG, neither of which were statistically significant. There were also no significant differences between groups in any of the secondary outcomes. Zinc was well tolerated, and compliance was high (88%). Conclusion: We believe our results are consistent with other Western clinical trial studies and do not support the use of supplemental zinc in populations with a Western diet. There may still be a role for supplemental zinc in the developing world where diets may be zinc deficient. Trial registration: Australian and New Zealand Clinical Trials Registry, ACTRN12618001120268. Registered on 6 July 2018.
- 22 April 2022
- Published by Springer Nature in Acta Diabetologica
- Vol. 59  (7) , 965-975
Open AccessThe effect of zinc supplementation on glucose homeostasis: a randomised double-blind placebo-controlled trial
Aims: The burden and health costs of Type 2 Diabetes Mellitus continue to increase globally and prevention strategies in at-risk people need to be explored. Previous work, in both animal models and humans, supports the role of zinc in improving glucose homeostasis. We, therefore, aimed to test the effectiveness of zinc supplementation on glycaemic control in pre-diabetic adults. Methods: We conducted a randomized, double-blind, placebo-controlled trial across 10 General Practitioner (GP) practices in NSW, Australia. The trial is known as Zinc in Preventing the Progression of pre-Diabetes (ZIPPeD)Study. Pre-diabetic (haemoglobin A1c [HbA1c] 5.7–6.4%, 39–46 mmol/mol) men and women (N = 98) were all assigned to a free state government telephone health coaching service (New South Wales Get Healthy Information and Coaching Service) and then randomised to either daily 30 mg zinc gluconate or placebo. Blood tests were collected at baseline, 1, 6 and 12 months for the primary outcomes (HbA1c, fasting blood glucose (FBG)); secondary outcomes included Homeostasis Model Assessment 2 (HOMA 2) parameters, lipids, body weight, height, waist circumference, blood pressure and pulse. Results: The baseline-adjusted mean group difference at 6 months, expressed as treatment–placebo, (95% CI) was −0.02 (−0.14, 0.11, p = 0.78) for HbA1c and 0.17 (−0.07, 0.42; p = 0.17) for FBG, neither of which were statistically significant. There were also no significant differences between groups in any of the secondary outcomes. Zinc was well tolerated, and compliance was high (88%). Conclusion: We believe our results are consistent with other Western clinical trial studies and do not support the use of supplemental zinc in populations with a Western diet. There may still be a role for supplemental zinc in the developing world where diets may be zinc deficient. Trial registration: Australian and New Zealand Clinical Trials Registry, ACTRN12618001120268. Registered on 6 July 2018.
- 1 January 2019
- Published by CSIRO Publishing in Australian Journal of Primary Health
- Vol. 25  (3) , 219-243
Hunter and New England Diabetes Alliance: innovative and integrated diabetes care delivery in general practice
Evidence-based standardised diabetes care is difficult to achieve in the community due to resource limitations, and lack of equitable access to specialist care leads to poor clinical outcomes. This study reports a quality improvement program in diabetes health care across a large health district challenged with significant rural and remote geography and limited specialist workforce. An integrated diabetes care model was implemented, linking specialist teams with primary care teams through capacity enhancing case-conferencing in general practice supported by comprehensive performance feedback with regular educational sessions. Initially, 20 practices were recruited and 456 patients were seen over 14 months, with significant improvements in clinical parameters. To date 80 practices, 307 general practitioners, 100 practice nurses and 1400 patients have participated in the Diabetes Alliance program and the program envisages enrolling 40 new practices per year, with a view to engage all 314 practices in the health district over time. Diabetes care in general practice appears suboptimal with significant variation in process measures. An integrated care model where specialist teams are engaged collaboratively with primary care teams in providing education, capacity enhancing case-conferences and performance monitoring may achieve improved health outcomes for people with diabetes.
- 1 January 2019
- Published by CSIRO Publishing in Australian Journal of Primary Health
- Vol. 25  (3) , 219-243
Hunter and New England Diabetes Alliance: innovative and integrated diabetes care delivery in general practice
Evidence-based standardised diabetes care is difficult to achieve in the community due to resource limitations, and lack of equitable access to specialist care leads to poor clinical outcomes. This study reports a quality improvement program in diabetes health care across a large health district challenged with significant rural and remote geography and limited specialist workforce. An integrated diabetes care model was implemented, linking specialist teams with primary care teams through capacity enhancing case-conferencing in general practice supported by comprehensive performance feedback with regular educational sessions. Initially, 20 practices were recruited and 456 patients were seen over 14 months, with significant improvements in clinical parameters. To date 80 practices, 307 general practitioners, 100 practice nurses and 1400 patients have participated in the Diabetes Alliance program and the program envisages enrolling 40 new practices per year, with a view to engage all 314 practices in the health district over time. Diabetes care in general practice appears suboptimal with significant variation in process measures. An integrated care model where specialist teams are engaged collaboratively with primary care teams in providing education, capacity enhancing case-conferences and performance monitoring may achieve improved health outcomes for people with diabetes.